Creator: Help Dementia Editorial Team
Published: 2026-04-02T10:13:28

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Lewy body sits at the center of this dementia and brain health question.

Lewy body dementia (LBD) and Alzheimer’s disease are often confused because they’re the two most common causes of dementia in older adults, but they differ fundamentally in what causes them, how they develop, and how they should be treated. The key difference comes down to proteins: Alzheimer’s is driven by amyloid-beta plaques and tau tangles in the brain, while Lewy body dementia is caused by alpha-synuclein deposits called Lewy bodies. These aren’t just academic distinctions—they directly affect which symptoms appear first, how quickly the disease progresses, and critically, which medications will help or harm the patient.

A 78-year-old man who develops stiffness, shuffling, and early vivid hallucinations might seem like he has typical Alzheimer’s, but if his symptoms actually point to Lewy body dementia and he receives standard Alzheimer’s medications or, worse, antipsychotics, those drugs could trigger dangerous reactions that dramatically worsen his condition. Getting the diagnosis right matters profoundly because Lewy body dementia is severely underdiagnosed—80% of patients are misdiagnosed initially—yet it’s the second most common cause of dementia after Alzheimer’s, affecting approximately 1.4 million Americans. This article explores how LBD and Alzheimer’s differ, why misdiagnosis happens so often, what happens when patients receive the wrong treatment, and what families should look for to ensure they get answers sooner rather than after months of seeing multiple doctors.

What Makes Lewy Body Dementia Distinct From Alzheimer’s?
How Symptoms Develop Differently in LBD Versus Alzheimer’s
Why 80% of LBD Patients Are Misdiagnosed and What That Costs
The Dangerous Consequences of Wrong Treatment
How Doctors Distinguish Lewy Body Dementia From Alzheimer’s
The Complication of Mixed Pathology
What Families Should Do to Avoid Misdiagnosis
Conclusion

What Makes Lewy Body Dementia Distinct From Alzheimer’s?

The biological distinction between these two diseases creates a cascade of differences in how they present and progress. Alzheimer’s typically begins with memory loss—forgetting recent conversations, misplacing keys, repeating questions. In contrast, Lewy body dementia often starts with movement symptoms: a shuffling gait, muscle stiffness, tremors similar to Parkinson’s disease, or slowness in performing everyday tasks. These movement problems emerge because Lewy bodies accumulate in the regions of the brain that control motor function, whereas Alzheimer’s plaques and tangles initially congregate in memory centers. This fundamental difference means a patient with early-stage Lewy body dementia might have relatively intact memory but struggle to walk steadily or coordinate their hands, a presentation that can fool both families and doctors who expect memory problems first. Visual hallucinations reveal another critical distinction. In Alzheimer’s disease, hallucinations typically don’t appear until the patient has been declining cognitively for three to four years or more.

In Lewy body dementia, vivid visual hallucinations can occur early in the disease—sometimes within the first year—and are considered a core diagnostic feature. Patients describe seeing people, animals, or detailed scenes that feel absolutely real; a woman with early LBD might insist she sees children playing in her living room, or a man might see his deceased brother standing in the kitchen. These hallucinations in Lewy body dementia are typically non-threatening and patients often remain aware they may not be real, whereas Alzheimer’s hallucinations tend to arrive after significant cognitive decline. The diagnostic criteria themselves capture this difference. Lewy body dementia requires cognitive decline plus at least two of these three features: visual hallucinations, parkinsonism (movement problems), or fluctuating alertness and attention. Alzheimer’s criteria focus on progressive memory loss with impaired judgment and thinking, eventually spreading to other cognitive domains. A neurologist seeing someone with stiffness, hallucinations, and cognitive fluctuations would immediately suspect Lewy body dementia, whereas a patient with pure memory decline would point toward Alzheimer’s.

What Makes Lewy Body Dementia Distinct From Alzheimer's?

How Symptoms Develop Differently in LBD Versus Alzheimer’s

The tempo and pattern of decline vary significantly between these diseases, which is why careful observation over time matters. Alzheimer’s typically follows a predictable progression: early memory loss, then gradual spread to language, judgment, and eventually physical function. Lewy body dementia, by contrast, is characterized by fluctuation—patients may be sharp and lucid one hour and confused and drowsy the next, with no clear pattern. One family member might visit and find their parent alert and conversational; another visits later that same day and finds them barely responsive. This fluctuation is so central to LBD that doctors specifically look for it when making a diagnosis. Research on early-stage or “prodromal” Lewy body dementia reveals which warning signs precede diagnosed disease by months or years.

In patients who later developed LBD, cognitive fluctuations appeared in 80% of those in the prodromal phase, REM sleep behavior disorder (acting out dreams, sometimes violently) occurred in 68.9%, motor symptoms like stiffness appeared in 46.7%, and visual hallucinations in 11.1%. This pattern suggests that Lewy body dementia often announces itself through sleep disturbances and movement changes before memory problems become apparent. However, this progression isn’t universal—some patients experience hallucinations as their first symptom, while others never develop clear movement problems if the Lewy bodies concentrate in cognitive rather than motor regions of the brain. This unpredictability is why LBD is so often missed; doctors and families are waiting for memory loss as the opening symptom, not sleep acting-out or stiffness. The speed of cognitive decline also differs. Alzheimer’s disease typically progresses over 8 to 12 years from diagnosis to severe dementia. Lewy body dementia generally progresses faster—often 5 to 8 years—which means time to diagnosis is even more critical because treatments and support services become necessary sooner.

Why 80% of LBD Patients Are Misdiagnosed and What That Costs

The statistics on misdiagnosis are sobering. Eighty percent of Lewy body dementia patients are initially misdiagnosed—commonly as Alzheimer’s disease, Parkinson’s disease, or psychiatric illness—and the average time to correct diagnosis is 18 months and multiple doctor visits. Autopsies reveal the scope of the problem: only 30% of people with dementia with Lewy bodies receive that diagnosis during their lifetime, meaning the vast majority live and die with an incorrect diagnosis on their medical record. In one clinical study, 75.8% of DLB patients without obvious parkinsonism were misdiagnosed as having Alzheimer’s disease. Why does this happen? Alzheimer’s disease is far more common and top-of-mind for most clinicians and families, so when an older adult begins to decline cognitively, Alzheimer’s is the default assumption. If hallucinations appear, doctors might assume they’re seeing side effects of medication or signs of delirium rather than a core feature of an entirely different disease.

Lewy body dementia remains less well-known outside neurology and geriatric medicine circles. Additionally, the overlap between diseases complicates the picture: approximately 50% of LBD patients also have overlapping Alzheimer’s disease pathology in their brains, so both diagnoses are technically true, which can confuse the clinical picture further. Misdiagnosis among women is particularly problematic. Female patients with Lewy body dementia are frequently overlooked, possibly because they may present with more behavioral or psychiatric symptoms initially rather than the textbook stiffness and tremor. A woman experiencing anxiety, depression, and hallucinations in her 70s might receive psychiatric treatment rather than neurological evaluation. The cost of misdiagnosis isn’t merely diagnostic—it leads to wrong treatments, delayed interventions, and families remaining confused about what’s happening to their loved ones.

Why 80% of LBD Patients Are Misdiagnosed and What That Costs

The Dangerous Consequences of Wrong Treatment

This is where the diagnosis becomes literally life-threatening. Antipsychotic medications like haloperidol, which might be prescribed to manage hallucinations in an Alzheimer’s patient, can trigger severe and dangerous reactions in Lewy body dementia. Patients have experienced extreme sedation, significant worsening of movement problems (sometimes to the point of immobility), dangerous drops in blood pressure, and in severe cases, sudden medical crises. A 75-year-old with LBD prescribed an antipsychotic for hallucinations might deteriorate catastrophically within days, becoming bedridden and unable to communicate, leading families to believe the disease has suddenly worsened when in reality the medication has triggered a crisis. This sensitivity to antipsychotics is specific to Lewy body dementia and stems from the alpha-synuclein pathology affecting dopamine regulation; antipsychotics that block dopamine can destabilize the already-disrupted dopamine system in LBD brains.

In contrast, a patient actually diagnosed with Lewy body dementia might benefit from entirely different medication strategies—sometimes low-dose cholinesterase inhibitors like donepezil, or in some cases, certain antidepressants that don’t cause the dangerous interactions seen with antipsychotics. The medication landscape has shifted further with the arrival of anti-amyloid monoclonal antibodies like lecanemab for Alzheimer’s disease. These newer treatments target amyloid plaques specifically. They won’t work for pure Lewy body dementia, and choosing the right therapeutic approach depends on knowing which disease the patient actually has. Some patients with the 50% overlap (both LBD and Alzheimer’s pathology) might benefit from these drugs, but that decision requires accurate diagnosis. Without it, families might pursue treatments that don’t address the actual biology driving decline.

How Doctors Distinguish Lewy Body Dementia From Alzheimer’s

Accurate diagnosis relies on recognizing the clinical pattern and, increasingly, on specialized tests. The first step is history and observation: a clinician should ask about the order of symptoms. Did movement problems come before memory problems? Are hallucinations present and visual? Is alertness fluctuating dramatically? Do sleep disturbances include vivid, acting-out dreams? These features, taken together, strongly suggest Lewy body dementia. However, the overlap and individual variation mean clinical assessment alone isn’t always reliable. Advanced imaging and biomarker tests provide more certainty. PET imaging can detect alpha-synuclein deposits, though this test isn’t widely available outside research or specialized memory clinics.

Amyloid and tau PET scans can show the different pathology characteristic of Alzheimer’s. Cerebrospinal fluid biomarkers—measured via lumbar puncture—can detect alpha-synuclein, phosphorylated tau, and amyloid ratios that distinguish between diseases. Blood tests measuring phosphorylated tau (p-tau) and amyloid ratios are increasingly available and can point toward Alzheimer’s versus Lewy body pathology. However, these advanced tests require access to specialty care and knowledgeable interpretation; a primary care doctor might not order them, which is why many patients with LBD see multiple doctors before reaching someone who suspects the right diagnosis. The DAT scan (dopamine transporter scan) can detect the degeneration of dopamine neurons characteristic of both Lewy body dementia and Parkinson’s disease, which helps distinguish Lewy-related diseases from Alzheimer’s but doesn’t definitively prove LBD on its own. A caveat: not all imaging findings are definitive during life. The most certain diagnosis still comes from autopsy—which is why the research on misdiagnosis relies so heavily on post-mortem findings, revealing how many people lived with the wrong diagnosis.

How Doctors Distinguish Lewy Body Dementia From Alzheimer's

The Complication of Mixed Pathology

About 50% of people with Lewy body dementia also have Alzheimer’s pathology—amyloid plaques and tau tangles—in addition to their Lewy bodies. These patients technically have both diseases, which is why the term “mixed dementia” exists. This overlap creates diagnostic and treatment challenges because their brains show multiple types of damage. A patient with both Alzheimer’s and Lewy body pathology might present with memory loss (Alzheimer’s signature) and hallucinations (Lewy body signature), making the disease profile less clear-cut.

For these patients, treatment decisions become more nuanced. Traditional Alzheimer’s medications might help the cognitive decline driven by Alzheimer’s pathology, but the clinician must still be cautious about antipsychotics because of the Lewy body component. Some mixed dementia patients benefit from combinations of approaches targeting both pathologies. This is why accurate diagnosis—or, in some cases, acceptance of true mixed pathology—is crucial; treatment should address the actual biology present, not guess based on assumptions.

What Families Should Do to Avoid Misdiagnosis

If a loved one is showing cognitive decline with prominent movement problems, early hallucinations, or fluctuating alertness, families should advocate for evaluation by a neurologist or geriatrician rather than relying on a primary care doctor alone. These specialists are more likely to recognize the Lewy body pattern and order the appropriate tests. Bringing a detailed timeline of symptoms—when they started, in what order—helps enormously. Mention hallucinations explicitly; don’t let them be minimized as “confusion” or “medication side effects.” Document whether the patient has developed REM sleep behavior disorder or other sleep disturbances, as these are early clues.

Families should also educate themselves about the risks of antipsychotics in Lewy body dementia before any psychiatric or behavioral medications are prescribed. If a clinician recommends an antipsychotic, ask directly whether they’ve ruled out Lewy body dementia. This isn’t being difficult; it’s preventing potentially serious harm. As diagnosis and treatment approaches evolve—with more accessible biomarker testing and growing awareness of LBD—the window to get the diagnosis right and start appropriate support is narrowing in a helpful direction.

Conclusion

Lewy body dementia and Alzheimer’s disease are fundamentally different diseases requiring different diagnostic approaches and treatment strategies. The key distinctions—Lewy bodies versus amyloid and tau, early movement and hallucination symptoms versus memory loss, sensitivity to antipsychotics—must be recognized to prevent harm. Given that 80% of LBD patients are initially misdiagnosed and that an antipsychotic prescribed in error can trigger serious decline, the stakes of getting the diagnosis right are very high.

If you’re noticing movement problems, early hallucinations, or fluctuating alertness in a family member, don’t accept a default Alzheimer’s diagnosis without deeper evaluation. Seek a neurologist’s assessment, document the symptom timeline, ask about diagnostic testing, and discuss medication safety specifically regarding antipsychotics. The months saved between initial symptoms and correct diagnosis are months your family can spend on the right support, the right medications, and the right expectations for the road ahead.